Moreover, clinical investigations highlight the robust efficacy of a co-targeting approach, combining epidermal growth factor (EGF) receptor (EGFR)-TKIs with crizotinib as targeted therapies, especially in metastatic NSCLC [17]. Here, EGFR is linked to non-small cell lung carcinoma.